Evidence base. The supplied records linked to P. Bao span bioinorganic phage nanomedicine , few-view CT reconstruction , ECF transporter structural biology , and reference-material isotope metrology . This breadth is unusual and raises a name-disambiguation red flag: multiple distinct researchers named Peng Bao likely contribute to these clusters (ferroelectrics/oxide electronics in the listed 52-paper record vs. the phage and prebiotic-chemistry works). Scores below should be read with that uncertainty.
Strengths. The flagship work appears in top venues (Science Advances, Nature Communications, ACS Catalysis-level venues) with multi-modal validation (TEM, ITC, mutagenesis, flow cytometry) and honest declared funding. The CT work reports full quantitative PSNR/RMSE/SSIM tables supporting a >6 dB PSNR gain over the nearest baseline .
Weaknesses and blindspots. Recurring issues: (1) small in-vivo samples (nβ3β8 mice/group) with no human validation ; (2) three-slice imaging validation only ; (3) recent prebiotics work carries a bold universal claim ('period five indicates autopoiesis') supported by only two reaction networks and no statistical tests β a marked rigor dip . Citation metrics (h-index 17, ~938 citations over 52 papers, ~18 cites/paper average) indicate solid but not field-leading impact, consistent with applied/niche contributions.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.